A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium

← catalyst calendar

NCT07382440 · readout ≤ 773 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

—

Status

Recruiting

Study type

Observational

Enrollment

120estimated

Sites

Country

Belgium

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-03-09

actual

When the study began enrolling

Primary completion

Sep 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Sep 2028

estimated

The whole study's end, after follow-up

First posted

2026-02-02

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-10

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Parkinson's Disease

Primary outcome

what the primary-completion date above is the date OF

Change From Baseline in OFF Time (hours) as measured by modified Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) IV

measured Up to approximately 6 months

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed